Related Experiment Video
Updated: Jun 14, 2026
09:02
Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
Published on: November 26, 2018
Genetic susceptibility variants for chronic lymphocytic leukemia
Susan L Slager1, Lynn R Goldin, Sara S Strom
1Mayo Clinic College of Medicine, 200 1st Street Southwest, Rochester, MN 55905, USA. slager@mayo.edu
Summary
Genetic variants near IRF4 and GRAMD1B increase chronic lymphocytic leukemia (CLL) risk. This study confirms previous findings, highlighting the genetic basis of CLL and the need for further research into specific causal single nucleotide polymorphisms (SNPs).
Area of Science:
- Genetics
- Oncology
- Hematology
Background:
- Chronic lymphocytic leukemia (CLL) has a significant genetic component.
- A prior genome-wide association study identified seven genetic variants associated with increased CLL risk in Europeans.
Purpose of the Study:
- To validate the association of previously identified genetic variants with CLL risk in an independent cohort.
- To investigate the role of specific single nucleotide polymorphisms (SNPs) and their linkage disequilibrium in CLL pathogenesis.
Main Methods:
- Case-control study design.
- Evaluation of seven specific SNPs and their linkage disequilibrium with CLL risk.
- Statistical analysis using trend tests and odds ratios (OR) with 95% confidence intervals (CI).
Main Results:
- Six of the seven evaluated SNPs showed a significant association with CLL risk (P trend < 0.05).
- Significant associations were observed for rs9378805 near IRF4 (OR, 1.47) and rs735665 near GRAMD1B (OR, 1.47).
- No significant association was found for SNP rs11083846 or its linked variants.
Conclusions:
- The study findings confirm the association of specific genetic variants with CLL risk.
- These results reinforce the genetic underpinnings of CLL etiology.
- Further research is required to identify causal SNPs and understand their functional mechanisms in CLL development.
Related Concept Videos
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:27Principles of Pharmacogenetics: Types of Genetic Variants
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:05Single Nucleotide Polymorphisms-SNPs
A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
01:11Genome-wide Association Studies-GWAS
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
02:30Histone Variants at the Centromere
Histone variants are the histone proteins with structural and sequence variations. These variants may be regarded as “mutant” forms that replace their canonical histone counterparts in the nucleosomes. Specific post-translational modifications on the histone variants enable further chromatin complexity and regulate tissue-specific gene expression. The most common histone variants are from histone H2A, H2B, and linker histone H1 families. However, several variants of histone H3 variants are also...